Amicus Therapeutics (FOLD) News Today → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free FOLD Stock Alerts $10.30 -0.24 (-2.28%) (As of 09:40 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVontobel Holding Ltd. Purchases New Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - April 21 at 5:24 AMAmicus Therapeutics Becomes Oversold (FOLD)nasdaq.com - April 14 at 7:38 PMPeregrine Capital Management LLC Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - April 10 at 9:49 AMNevada’s Lee joins on to Amicus Brief in SCOTUS abortion casemsn.com - March 30 at 10:58 AMNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion casemsn.com - March 29 at 6:55 PMAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5%marketbeat.com - March 28 at 4:33 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Vanguard Group Inc.marketbeat.com - March 27 at 4:26 AMZacks Research Comments on Amicus Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:FOLD)marketbeat.com - March 22 at 7:49 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q3 2024 Earnings of $0.01 Per Share, Zacks Research Forecastsmarketbeat.com - March 21 at 8:05 AMAmicus Therapeutics Target of Unusually High Options Trading (NASDAQ:FOLD)marketbeat.com - March 20 at 11:34 AMAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Reportglobenewswire.com - March 20 at 7:00 AMJPMorgan Chase & Co. Trims Amicus Therapeutics (NASDAQ:FOLD) Target Price to $19.00marketbeat.com - March 18 at 2:54 PMWellington Management Group LLP Sells 296,607 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 18 at 4:54 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by American Century Companies Inc.marketbeat.com - March 17 at 4:46 AMFOLD Jul 2024 12.000 callca.finance.yahoo.com - March 16 at 11:40 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Growth in Short Interestmarketbeat.com - March 16 at 6:46 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells $100,500.00 in Stockinsidertrades.com - March 16 at 10:15 AMJPMorgan Chase & Co. Sells 432,962 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 12 at 6:20 AMEnvestnet Asset Management Inc. Purchases 248,220 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 8 at 4:16 AMFOLD Oct 2024 12.000 callfinance.yahoo.com - March 7 at 11:20 PMFOLD Jan 2025 12.000 putfinance.yahoo.com - March 7 at 6:20 PMFOLD Jul 2024 9.000 putfinance.yahoo.com - March 7 at 6:20 PMInvesco Ltd. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 7 at 4:40 AMDirector Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)finance.yahoo.com - March 7 at 3:18 AMAmicus Therapeutics Stock Sees RS Rating Improve To 74finance.yahoo.com - March 6 at 5:17 PMFmr LLC Has $33.78 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 3 at 5:14 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?finance.yahoo.com - March 2 at 10:11 AMAmicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 2:07 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)markets.businessinsider.com - March 1 at 2:07 PMMPM Bioimpact LLC Buys 200,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - March 1 at 10:19 AMBuy Rating Affirmed: Amicus’s Strong Product Launch and Growth Trajectorymarkets.businessinsider.com - March 1 at 8:56 AMAmicus Therapeutics Full Year 2023 Earnings: EPS Misses Expectationsfinance.yahoo.com - March 1 at 8:56 AMAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2024globenewswire.com - March 1 at 7:00 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 1:00 PMAmicus Therapeutics: Expect Improved Commercial Momentum In 2024seekingalpha.com - February 29 at 10:05 AMQ4 2023 Amicus Therapeutics Inc Earnings Callfinance.yahoo.com - February 29 at 2:19 AMBuy Rating Affirmed for Amicus with Strong Growth and Promising Outlookmarkets.businessinsider.com - February 28 at 8:29 PMAmicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updatesfinanznachrichten.de - February 28 at 10:29 AMAmicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ...finance.yahoo.com - February 28 at 10:29 AMAmicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-linemsn.com - February 28 at 10:29 AMAmicus Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 28 at 10:09 AMAmicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updatesglobenewswire.com - February 28 at 7:00 AMAmicus Therapeutics Q4 2023 Earnings Previewmsn.com - February 27 at 1:04 PMDeutsche Bank AG Sells 6,112,106 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - February 27 at 4:50 AMAmicus Therapeutics, Inc. to Post FY2024 Earnings of $0.00 Per Share, Zacks Research Forecasts (NASDAQ:FOLD)marketbeat.com - February 23 at 7:48 AMZacks Research Comments on Amicus Therapeutics, Inc.'s Q4 2024 Earnings (NASDAQ:FOLD)marketbeat.com - February 22 at 7:50 AMCharles Schwab Investment Management Inc. Has $26.49 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - February 22 at 4:32 AMRafferty Asset Management LLC Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)marketbeat.com - February 18 at 7:28 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - February 17 at 1:38 AMAmicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024finance.yahoo.com - February 15 at 10:47 AM Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. FOLD Media Mentions By Week FOLD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼1.790.44▲Average Medical News Sentiment FOLD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼14▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALKS News GERN News BBIO News MDGL News DVAX News LGND News IRWD News MNKD News BPMC News INVA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
